REST and RASSF1A Tumor Suppressor Genes in Peripheral Blood: Potential Molecular Markers in Breast Cancer
International Journal of Molecular Sciences · 18.03.2026 · 27 (6) · 2752
DOI: 10.3390/ijms27062752 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.03.2026. Verfasst von Maria Eduarda R de Oliveira und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Análises Clínicas, Centro Universitário FMABC, Av. Principe de Gales, 821, Santo André 09060-950, São Paulo, Brazil. Hauptthemen laut MEDLINE: Breast Neoplasms, Tumor Suppressor Proteins, Biomarkers, Tumor, Repressor Proteins. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Tumor suppressor genes, such as RASSF1A and REST, play a central role in regulating cell proliferation. RASSF1A is frequently inactivated in various cancers, being associated with poor prognosis and metastasis. REST loss promotes the activation of genes related to invasion and estrogen sensitivity. We aimed to evaluate the expression of REST and RASSF1A in peripheral blood of breast cancer patients at different treatment stages and to associate the results with clinical and laboratory variables. Peripheral blood samples from breast cancer patients were collected at diagnosis and at 3 and 6 months after the start of chemotherapy; blood samples from healthy women were also collected. Gene expression was quantified by qPCR and associated with clinical variables. REST expression was significantly lower in patients (p < 0.0001), showing a negative correlation with the BIRADS classification and an AUC of 0.72. RASSF1A showed no significant difference between groups but was negatively correlated with heparanase (r = −0.4213; p < 0.0001). No relevant variations in gene expression were observed among the serial collections, nor associations with histological type. Downregulation of REST expression in the peripheral blood of breast cancer patients suggests its potential as an auxiliary biomarker for diagnosis and risk stratification. RASSF1A was correlated with mechanisms associated with tumor progression but did not differentiate patients from controls.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Análises Clínicas, Centro Universitário FMABC, Av. Principe de Gales, 821, Santo André 09060-950, São Paulo, Brazil.
- Departamento de Ciências Farmacêuticas, Universidade Federal de São Paulo, R. Prof. Artur Riedel, 275, Diadema 09972-270, São Paulo, Brazil.
ORCID-Profile: Estella F Silvestri, Isabella D R Trufelli, Glaucia L da Veiga, Fernando Luiz A Fonseca
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Oliveira, M. E. R., Silva, M. P., Silvestri, E. F., Sanches, S. F., Trufelli, I. D. R., Fabbrini, L. F. B., Veiga, G. L. D., Fonseca, F. L. A., & Alves, B. D. C. A. (2026). REST and RASSF1A Tumor Suppressor Genes in Peripheral Blood: Potential Molecular Markers in Breast Cancer. International Journal of Molecular Sciences, 27(6), 2752. https://doi.org/10.3390/ijms27062752
Vancouver
Oliveira MER, Silva MP, Silvestri EF, Sanches SF, Trufelli IDR, Fabbrini LFB, et al. REST and RASSF1A Tumor Suppressor Genes in Peripheral Blood: Potential Molecular Markers in Breast Cancer. International Journal of Molecular Sciences. 2026;27(6):2752. doi:10.3390/ijms27062752
BibTeX
@article{Oliveira2026,
author = {Oliveira, Maria Eduarda R de and Silva, Marina P and Silvestri, Estella F and Sanches, Samia F and Trufelli, Isabella D R and Fabbrini, Ludmila F B and Veiga, Glaucia L da and Fonseca, Fernando Luiz A and Alves, Beatriz da C A},
title = {REST and RASSF1A Tumor Suppressor Genes in Peripheral Blood: Potential Molecular Markers in Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2752},
doi = {10.3390/ijms27062752}
}
EUVIMED